Form 4: Capricor Therapeutics Director Exercises Stock Options and Acquires Shares

David B. Musket, a director at Capricor Therapeutics, exercised stock options to acquire shares at $1.39 per share on April 23, 2024.

Summary

• On April 23, 2024, David B. Musket, a director of Capricor Therapeutics, exercised stock options to acquire 16,156 shares of common stock at a price of $1.39 per share.
• Following the transaction, Musket directly owns 47,692 shares and indirectly owns 7,096 shares held in an IRA.
• The exercised options were granted on various dates (January 3, 2017, January 2, 2018, and August 8, 2019) and adjusted for a reverse stock split and share reprice.
• The options vested monthly over different periods.

Sentiment

Score: 6

Explanation: Neutral sentiment. The filing simply reports the exercise of stock options by a director, which is a routine transaction. It doesn't inherently indicate positive or negative sentiment about the company's performance.

Positives

• Director's exercise of stock options may indicate confidence in the company's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders (directors, officers, and 10% owners) of a publicly traded company buy or sell the company's securities. These filings provide transparency into insider transactions and can be used by investors to gauge management's sentiment about the company's prospects.

Comparison to Industry Standards

• Form 4 filings are a standard regulatory requirement for publicly traded companies in the United States, ensuring transparency of insider transactions.
• Companies like Amgen, Biogen, and Gilead Sciences also have similar Form 4 filings when their directors or officers trade company stock.

Stakeholder Impact

• The transaction may have a minor impact on shareholders by slightly increasing the number of outstanding shares.

Key Dates